Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are
More
Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are
More
With 350+ participants representing the core of China’s market, the Biopharma Development & Production Week is back to spur industry learning, showcase
More
Unlike generic medicines where the active ingredients are identical, biosimilars – by definition – are not likely to be identical
More